MainProviding guidance to industry using a variety of mechanisms is intended to assist with the development of high quality, generic drug products by a number of potential manufacturers. Guidance in the form of meetings is especially valuable for developing more complex products such as dry powder inhalers or topical products for which generics are not currently available. FDA’s scientific guidance documents are intended to maximize both industry and OGD resources by minimizing less than optimal product development and applications that cannot be approved. <br>These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research. </b> Number0

FY 2010 Total: 25

Oct 20098Nov 20092Dec 20090Jan 20107Feb 20102Mar 20100Apr 20104May 20100Jun 20101Jul 20101Aug 20100Sep 201000

FY 2011 Total: 12

Oct 20102Nov 20101Dec 20101Jan 20110Feb 20112Mar 20110Apr 20110May 20110Jun 20112Jul 20112Aug 20111Sep 201110

FY 2012 YTD: 0

Oct 20110Nov 20110Dec 20110Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012MainNumber0

FY 2010 Total: 38

Oct 200916Nov 20091Dec 20090Jan 20101Feb 20102Mar 20105Apr 20108May 20104Jun 20100Jul 20100Aug 20100Sep 201010

FY 2011 Total: 9

Oct 20101Nov 20102Dec 20100Jan 20110Feb 20111Mar 20110Apr 20111May 20111Jun 20111Jul 20110Aug 20111Sep 201110

FY 2012 YTD: 0

Oct 20110Nov 20110Dec 20110Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012MainNumber0

FY 2010 Total: 2

Oct 20091Nov 20090Dec 20090Jan 20100Feb 20100Mar 20101Apr 20100May 20100Jun 20100Jul 20100Aug 20100Sep 201000

FY 2011 Total: 1

Oct 20100Nov 20101Dec 20100Jan 20110Feb 20110Mar 20110Apr 20110May 20110Jun 20110Jul 20110Aug 20110Sep 201100

FY 2012 YTD: 0

Oct 20110Nov 20110Dec 20110Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htmFDA-TRACK CDER Dashboard ਍††਍਍਍਍਍਍਍